drugset / Trial / NCT04510922

Lundbeck TOMs Orthostatic Hypotension

NCT04510922

Phase 4 Completed 9 enrolled Alberto Espay, MD, MSc Lundbeck LLC · collab
Non-randomizedSingle-groupOpen-labelOther

Summary

Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure levels upon standing from a seated position, may affect approximately one in three patients with Parkinson's disease (PD). It usually presents as dizziness, lightheadedness, feeling faint, or feeling like you might black out while standing. This can significantly impact the quality of life (QoL) of PD patients, resulting in difficulties with balance, walking, and increased risk of falls. The main aim of this study is to evaluate whether the use of technological devices (a computerized system for analyzing abnormalities in walking in clinical settings and a wearable sensor to detect changes in postural unsteadiness in the home environment) may improve the detection of complications and the response to medical therapies for OH in patients with PD.

Timeline

Start
2019-02-11
Primary completion
2020-12-31
Completion
2020-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Droxidopa Small molecule 600 mg